The decisive role of molecular pathology in presumed somatic metastases of type II testicular germ cell tumors: report of 2 cases.
Case report
Gain 12p
Metastasis
Molecular diagnostics
Testicular germ cell tumor
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
25 Jul 2020
25 Jul 2020
Historique:
received:
26
04
2020
accepted:
14
07
2020
entrez:
27
7
2020
pubmed:
28
7
2020
medline:
9
6
2021
Statut:
epublish
Résumé
Molecular diagnostics can be decisive in the differential diagnosis between a somatic metastasis of type II testicular germ cell tumor (TGCT) or a second primary carcinoma. This is in line with recent recommendations from the International Society of Urological Pathology, based on an international survey which showed that molecular testing is currently only performed by a minority of urological pathologists. This case report illustrates the necessity of molecular testing in two patients with a history of type II TGCT and a metastatic (retro) peritoneal carcinoma years later. The genetic hallmark of type II TGCT, chromosome 12p gain, was studied by fluorescence in situ hybridization and whole genome methylation profiling in case 1, and by single nucleotide polymorphism (SNP)-array in case 2. Next generation sequencing (NGS) was used to further explore clonality between the primary TGCT and peritoneal metastasis in case 2. In case 1, chromosome 12p gain was found in the primary type II TGCT and in the acinar cell carcinoma of the metastatic malignancy. In case 2, SNP array showed 12p gain in the epithelial component of the primary teratomatous TGCT but not in the peritoneal adenocarcinoma. Furthermore, NGS showed no mutations in the primary teratomatous TGCT but a KRAS and GNAS mutation in the peritoneal adenocarcinoma, suggestive of an appendicular origin. Without the molecular data, both cases would have been regarded as a metastatic TGCT with development of somatic-type malignancy, which appeared a wrong diagnosis for case 2. These cases demonstrate the importance of molecular methods as an adjunct in today's pathology practice.
Sections du résumé
BACKGROUND
BACKGROUND
Molecular diagnostics can be decisive in the differential diagnosis between a somatic metastasis of type II testicular germ cell tumor (TGCT) or a second primary carcinoma. This is in line with recent recommendations from the International Society of Urological Pathology, based on an international survey which showed that molecular testing is currently only performed by a minority of urological pathologists.
CASE PRESENTATIONS
METHODS
This case report illustrates the necessity of molecular testing in two patients with a history of type II TGCT and a metastatic (retro) peritoneal carcinoma years later. The genetic hallmark of type II TGCT, chromosome 12p gain, was studied by fluorescence in situ hybridization and whole genome methylation profiling in case 1, and by single nucleotide polymorphism (SNP)-array in case 2. Next generation sequencing (NGS) was used to further explore clonality between the primary TGCT and peritoneal metastasis in case 2. In case 1, chromosome 12p gain was found in the primary type II TGCT and in the acinar cell carcinoma of the metastatic malignancy. In case 2, SNP array showed 12p gain in the epithelial component of the primary teratomatous TGCT but not in the peritoneal adenocarcinoma. Furthermore, NGS showed no mutations in the primary teratomatous TGCT but a KRAS and GNAS mutation in the peritoneal adenocarcinoma, suggestive of an appendicular origin.
CONCLUSIONS
CONCLUSIONS
Without the molecular data, both cases would have been regarded as a metastatic TGCT with development of somatic-type malignancy, which appeared a wrong diagnosis for case 2. These cases demonstrate the importance of molecular methods as an adjunct in today's pathology practice.
Identifiants
pubmed: 32711552
doi: 10.1186/s13000-020-01011-0
pii: 10.1186/s13000-020-01011-0
pmc: PMC7382836
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
99Références
Nat Rev Cancer. 2005 Mar;5(3):210-22
pubmed: 15738984
Cureus. 2016 Apr 01;8(4):e551
pubmed: 27182465
Am J Surg Pathol. 2013 Dec;37(12):1862-70
pubmed: 24061513
Am J Surg Pathol. 2014 Mar;38(3):410-20
pubmed: 24525512
Matrix Biol. 2012 Sep-Oct;31(7-8):421-31
pubmed: 23199377
Genome Med. 2014 May 29;6(5):43
pubmed: 24944587
Am J Surg Pathol. 2020 Jul;44(7):e66-e79
pubmed: 32205480
Urol Oncol. 2008 Nov-Dec;26(6):595-9
pubmed: 18367105
Cancer. 2009 Jun 15;115(12):2640-51
pubmed: 19365862
Diagn Cytopathol. 2019 Sep;47(9):930-934
pubmed: 31120625
J Urol. 1998 Mar;159(3):859-63
pubmed: 9474169
Nature. 2018 Jun;558(7711):529-530
pubmed: 29946098
Am J Surg Pathol. 2014 Oct;38(10):1396-409
pubmed: 24921638
Methods Mol Biol. 2019;1908:1-17
pubmed: 30649717
Cancer. 2015 Dec 1;121(23):4181-9
pubmed: 26280359
Am J Surg Pathol. 2000 Feb;24(2):257-73
pubmed: 10680894
Am J Surg Pathol. 2012 Feb;36(2):311-5
pubmed: 22251944
Cancer. 1985 Aug 15;56(4):860-3
pubmed: 2990657
J Urol. 1998 Jan;159(1):133-8
pubmed: 9400455
Int J Cancer. 2000 Dec 1;88(5):772-7
pubmed: 11072247
Dis Esophagus. 2012 Sep-Oct;25(7):630-7
pubmed: 22221671
Int J Urol. 2003 Sep;10(9):505-9
pubmed: 12941133
Pancreas. 2019 Jan;48(1):135-138
pubmed: 30531244
Mod Pathol. 2006 Apr;19(4):611-5
pubmed: 16554737
J Clin Oncol. 2003 Dec 1;21(23):4285-91
pubmed: 14645417
Genes Chromosomes Cancer. 2011 Dec;50(12):1033-42
pubmed: 21987446
Genes Chromosomes Cancer. 2002 Jun;34(2):211-23
pubmed: 11979555
PLoS One. 2016 Feb 26;11(2):e0149405
pubmed: 26919633
J Clin Pathol. 2018 Apr;71(4):285-290
pubmed: 29113995
APMIS. 2003 Jan;111(1):161-71; discussion 172-3
pubmed: 12752258